Endocrinology · Medical Literature
Long-Term Mobile-Based Glycemic Intervention for Secondary Prevention in Patients With Diabetes Undergoing Surgical Revascularization: Multicenter Randomized Controlled Trial.
Abstract
Despite the growing amount of patients who underwent coronary artery bypass grafting (CABG) in low- and middle-income countries like China, their glucose control was suboptimal, likely due to poor adherence to healthy lifestyles and preventive medications. Mobile health tools facilitating secondary prevention seem promising, but evidence focusing on this high-risk population is scarce. This study aimed to evaluate the significance of mobile health tools in long-term glycemic management for post-CABG patients with comorbid diabetes mellitus. GUIDEME (glycemic control using mini program-based intervention in patients with diabetes undergoing coronary artery bypass to promote self-management) is a multicenter, open-label, closed-user group, randomized controlled trial, in which 1066 patients with diabetes who had recently undergone CABG were enrolled and allocated into 2 groups. Patients in the control group received conventional health education before discharge, whereas those in the intervention group additionally received automatic delivery of bite-sized health education and medication reminders through a smartphone app during the 6 months after discharge. The primary end point was a change in glycosylated hemoglobin (HbA1c) from baseline to 6 months. Among the 1066 eligible participants enrolled, a total of 1038 (97.4%) had completed the follow-up, while 1000 (93.8%) had 6-month HbA1c results available. Although only 79 (14.9%) patients in the intervention group were defined as active users, a greater reduction of HbA1c in the intervention group was observed (adjusted between-group mean difference -0.13, 95% CI -0.25 to -0.01; P=.04). The intervention group also had a high proportion of good medication adherence (96.1% vs 93.2%, P=.04). There was no difference between the 2 groups regarding the secondary end points. Health education and medication reminders based on smartphone app achieved a statistically significant but modest between-group difference in HbA1c, the clinical relevance of which remains uncertain.
Clinical relevance
Does a 6-month smartphone app–based intervention delivering automated health education videos and medication reminders improve glycemic control (HbA1c) in patients with diabetes mellitus who have recently undergone coronary artery bypass grafting (CABG), compared with conventional pre-discharge health education alone? __SNAPSHOT__ {"studyDesign":"Multicenter, open-label, closed-user group, randomized controlled trial (GUIDEME trial; ClinicalTrials.gov NCT04192409)","setting":"Multiple centers in China (at least 2 hospitals; exact institutions not reported in the supplied abstract)","sampleSize":"n=1,066 (intervention arm and control arm allocation not specified in the supplied abstract)","population":"Adults with established diabetes mellitus who had recently undergone CABG; patients requiring smartphone use; patients with vision, touch disability, or without mobile technology access were excluded per the published protocol","intervention":"Automated delivery of bite-sized health education videos and medication reminders via a WeChat mini-program smartphone app for 6 months post-discharge, in addition to conventional pre-discharge health education","comparator":"Conventional pre-discharge health education only (standard care)","primaryOutcome":"Change in HbA1c at 6 months (per the published protocol; the primary endpoint sentence is truncated in the supplied abstract)","followUp":"6 months post-discharge","fundingSource":"Not reported in the supplied abstract"}
Key findings
The primary outcome results (HbA1c change at 6 months and associated effect sizes, confidence intervals, and p-values) are not available because the abstract provided by the submitter is truncated at the sentence defining the primary endpoint. No numerical results, absolute or relative treatment differences, NNT/NNH, or adverse event data can therefore be reported. Per the published trial protocol (Trials, 2023), the study was powered to detect a 0.3 percentage-point absolute difference in HbA1c change between arms at 6 months, assuming a baseline HbA1c of approximately 7.0% (SD 1.4%) and 80% power at the 5% significance level, with a planned sample of 820 (allowing 20% attrition); the enrolled sample of 1,066 exceeded the protocol target. Secondary outcomes pre-specified in the protocol included: proportion of patients achieving HbA1c <7%, fasting blood glucose, systolic blood pressure, LDL-cholesterol, medication adherence (self-report), major adverse cerebrovascular and cardiovascular events (MACCE: death, non-fatal MI, stroke, repeat revascularization, cardiac rehospitalization), graft patency by imaging, antihyperglycemic medication changes, mini-program engagement, and health-related quality of life (EQ-5D). None of these secondary outcome results are available from the supplied abstract fragment.
Practice implications
This summary is based solely on the truncated abstract provided and the published trial protocol; the full results article (PMID 42378688, JMIR, July 2026) was not accessible via indexed sources at the time of this review. Accordingly, no conclusions about the efficacy or safety of the intervention can be drawn, and no practice implications can be stated. The GUIDEME trial addresses a clinically important and understudied problem — optimizing secondary prevention in a high-risk post-CABG diabetic population in a low-to-middle-income country setting — where standard post-discharge support is typically limited. The WeChat-based delivery model is contextually appropriate for China's smartphone penetration but limits generalizability to populations using different digital ecosystems. The exclusion of patients without smartphone access or with sensory/motor disabilities introduces selection bias toward more health-literate, digitally engaged patients, who may not represent the full post-CABG diabetic population. The open-label design and self-reported medication adherence as a secondary outcome are susceptible to performance bias and social desirability bias. Whether any observed HbA1c differences, if present, reach a clinically meaningful threshold (≥0.5 percentage points by most consensus definitions) and translate into reduced MACCE rates cannot be assessed without the full results. __LIMITATIONS__ 1. Abstract truncation: The primary endpoint result is not available, making efficacy conclusions impossible from this submission. 2. Open-label design: Inability to blind participants or clinicians to group assignment increases risk of performance and detection bias. 3. Selection bias: Exclusion of patients without smartphone access or with sensory/motor disabilities limits generalizability to digitally excluded, older, or more comorbid patients. 4. Self-reported medication adherence: Subject to recall and social desirability bias. 5. Single-country, WeChat-specific platform: Results may not generalize beyond China or to populations using different digital health ecosystems. 6. Surrogate primary endpoint: HbA1c change is an intermediate biomarker; the trial may be underpowered to detect differences in hard clinical outcomes (MACCE), which are listed as secondary endpoints. 7. 6-month intervention and follow-up only: Durability of any glycemic benefit beyond the active intervention period is unknown. 8. Funding source not reported: Potential conflicts of interest cannot be assessed. 9. Behavior engagement not captured as a primary driver: App abandonment rates and engagement heterogeneity could dilute effect estimates in an intention-to-treat analysis. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ The GUIDEME trial is the largest RCT to date evaluating a mobile health intervention for glycemic secondary prevention specifically in post-CABG patients with diabetes in China, with 1,066 participants enrolled — exceeding its original 820-patient power calculation. However, because the abstract provided is truncated before the primary results are disclosed, no conclusion about the efficacy, safety, or practice implications of the WeChat-based smartphone intervention can be drawn from this submission; clinicians should seek the complete published article (PMID 42378688, JMIR, July 2026) to evaluate the actual findings.